JP2016530208A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016530208A5 JP2016530208A5 JP2016515414A JP2016515414A JP2016530208A5 JP 2016530208 A5 JP2016530208 A5 JP 2016530208A5 JP 2016515414 A JP2016515414 A JP 2016515414A JP 2016515414 A JP2016515414 A JP 2016515414A JP 2016530208 A5 JP2016530208 A5 JP 2016530208A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- combination
- methyl
- trifluoromethyl
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 84
- 150000001875 compounds Chemical class 0.000 claims description 35
- 201000011510 cancer Diseases 0.000 claims description 31
- 150000003839 salts Chemical class 0.000 claims description 26
- 239000011780 sodium chloride Substances 0.000 claims description 26
- 239000012453 solvate Substances 0.000 claims description 18
- WXCXUHSOUPDCQV-UHFFFAOYSA-N Enzalutamide Chemical compound C1=C(F)C(C(=O)NC)=CC=C1N1C(C)(C)C(=O)N(C=2C=C(C(C#N)=CC=2)C(F)(F)F)C1=S WXCXUHSOUPDCQV-UHFFFAOYSA-N 0.000 claims description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims description 17
- -1 hydrate Chemical compound 0.000 claims description 12
- 206010024324 Leukaemias Diseases 0.000 claims description 11
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 10
- XTKLTGBKIDQGQL-UHFFFAOYSA-N 2-methyl-1-[[2-methyl-3-(trifluoromethyl)phenyl]methyl]-6-morpholin-4-ylbenzimidazole-4-carboxylic acid Chemical compound CC1=NC2=C(C(O)=O)C=C(N3CCOCC3)C=C2N1CC1=CC=CC(C(F)(F)F)=C1C XTKLTGBKIDQGQL-UHFFFAOYSA-N 0.000 claims description 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 8
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 8
- 210000004027 cells Anatomy 0.000 claims description 7
- 239000003085 diluting agent Substances 0.000 claims description 7
- 239000003937 drug carrier Substances 0.000 claims description 7
- NAGFMACWWJYORB-UHFFFAOYSA-N 2-fluoro-N-methylbenzamide Chemical compound CNC(=O)C1=CC=CC=C1F NAGFMACWWJYORB-UHFFFAOYSA-N 0.000 claims description 6
- 239000007983 Tris buffer Substances 0.000 claims description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 6
- 238000002560 therapeutic procedure Methods 0.000 claims description 6
- 239000007787 solid Substances 0.000 claims description 5
- 206010000880 Acute myeloid leukaemia Diseases 0.000 claims description 4
- MVPPADPHJFYWMZ-UHFFFAOYSA-N Chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 claims description 4
- 206010060862 Prostate cancer Diseases 0.000 claims description 4
- 206010038389 Renal cancer Diseases 0.000 claims description 4
- 208000000389 T-Cell Leukemia Diseases 0.000 claims description 4
- 239000000969 carrier Substances 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N iso-propanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 4
- 201000010982 kidney cancer Diseases 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- AMQJEAYHLZJPGS-UHFFFAOYSA-N n-pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 claims description 4
- 206010025323 Lymphomas Diseases 0.000 claims description 3
- 206010025310 Other lymphomas Diseases 0.000 claims description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 3
- 230000001154 acute Effects 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 201000009251 multiple myeloma Diseases 0.000 claims description 3
- VVQNAFBGAWCMLU-UHFFFAOYSA-N 1H-benzimidazole-4-carboxylic acid Chemical compound OC(=O)C1=CC=CC2=C1N=CN2 VVQNAFBGAWCMLU-UHFFFAOYSA-N 0.000 claims description 2
- 206010003571 Astrocytoma Diseases 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000009899 Burkitt Lymphoma Diseases 0.000 claims description 2
- KGKXRSODGHRQDM-UHFFFAOYSA-N Cc1nc2ccc(cc2n1Cc1cccc(c1C)C(F)(F)F)N1CCOCC1 Chemical compound Cc1nc2ccc(cc2n1Cc1cccc(c1C)C(F)(F)F)N1CCOCC1 KGKXRSODGHRQDM-UHFFFAOYSA-N 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 210000003467 Cheek Anatomy 0.000 claims description 2
- 206010008958 Chronic lymphocytic leukaemia Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 201000002847 Cowden syndrome Diseases 0.000 claims description 2
- 206010051906 Cowden's disease Diseases 0.000 claims description 2
- 206010014967 Ependymoma Diseases 0.000 claims description 2
- 206010015281 Erythroleukaemia Diseases 0.000 claims description 2
- 208000006168 Ewing Sarcoma Diseases 0.000 claims description 2
- 206010017758 Gastric cancer Diseases 0.000 claims description 2
- 208000007569 Giant Cell Tumors Diseases 0.000 claims description 2
- 208000005017 Glioblastoma Diseases 0.000 claims description 2
- 206010018338 Glioma Diseases 0.000 claims description 2
- 206010073071 Hepatocellular carcinoma Diseases 0.000 claims description 2
- 208000005726 Inflammatory Breast Neoplasms Diseases 0.000 claims description 2
- 206010021980 Inflammatory carcinoma of the breast Diseases 0.000 claims description 2
- PHTQWCKDNZKARW-UHFFFAOYSA-N Isoamyl alcohol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 claims description 2
- 208000009503 Leukemia, Erythroblastic, Acute Diseases 0.000 claims description 2
- 208000000429 Leukemia, Lymphocytic, Chronic, B-Cell Diseases 0.000 claims description 2
- 208000008456 Leukemia, Myelogenous, Chronic, BCR-ABL Positive Diseases 0.000 claims description 2
- 208000007046 Leukemia, Myeloid, Acute Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 206010025650 Malignant melanoma Diseases 0.000 claims description 2
- 208000000172 Medulloblastoma Diseases 0.000 claims description 2
- 206010027406 Mesothelioma Diseases 0.000 claims description 2
- 208000008770 Multiple Hamartoma Syndrome Diseases 0.000 claims description 2
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims description 2
- 206010029260 Neuroblastoma Diseases 0.000 claims description 2
- 210000000440 Neutrophils Anatomy 0.000 claims description 2
- LYGJENNIWJXYER-UHFFFAOYSA-N Nitromethane Chemical compound C[N+]([O-])=O LYGJENNIWJXYER-UHFFFAOYSA-N 0.000 claims description 2
- 206010029592 Non-Hodgkin's lymphomas Diseases 0.000 claims description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 102000014160 PTEN Phosphohydrolase Human genes 0.000 claims description 2
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 claims description 2
- 208000008443 Pancreatic Carcinoma Diseases 0.000 claims description 2
- 208000007452 Plasmacytoma Diseases 0.000 claims description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 2
- 206010061934 Salivary gland cancer Diseases 0.000 claims description 2
- 206010039491 Sarcoma Diseases 0.000 claims description 2
- 206010042971 T-cell lymphoma Diseases 0.000 claims description 2
- 206010047741 Vulval cancer Diseases 0.000 claims description 2
- 208000008383 Wilms Tumor Diseases 0.000 claims description 2
- 201000005510 acute lymphocytic leukemia Diseases 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 230000001684 chronic Effects 0.000 claims description 2
- 201000006934 chronic myeloid leukemia Diseases 0.000 claims description 2
- 230000002950 deficient Effects 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 201000004101 esophageal cancer Diseases 0.000 claims description 2
- 201000003444 follicular lymphoma Diseases 0.000 claims description 2
- 230000002496 gastric Effects 0.000 claims description 2
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 claims description 2
- 201000010915 glioblastoma multiforme Diseases 0.000 claims description 2
- 201000009277 hairy cell leukemia Diseases 0.000 claims description 2
- 201000010536 head and neck cancer Diseases 0.000 claims description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 201000008806 mesenchymal cell neoplasm Diseases 0.000 claims description 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 2
- 201000008026 nephroblastoma Diseases 0.000 claims description 2
- 201000008968 osteosarcoma Diseases 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 201000010874 syndrome Diseases 0.000 claims description 2
- 201000002510 thyroid cancer Diseases 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 210000004696 Endometrium Anatomy 0.000 claims 1
- 210000003593 Megakaryocytes Anatomy 0.000 claims 1
- 210000001550 Testis Anatomy 0.000 claims 1
- 239000007972 injectable composition Substances 0.000 claims 1
- 239000008247 solid mixture Substances 0.000 claims 1
- 102000003952 Caspase 3 Human genes 0.000 description 4
- 108090000397 Caspase 3 Proteins 0.000 description 4
- 102000004041 Caspase 7 Human genes 0.000 description 4
- 108090000567 Caspase 7 Proteins 0.000 description 4
- 239000002609 media Substances 0.000 description 3
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- ZPKCFVXUDUWSBB-UHFFFAOYSA-N 1-morpholin-4-ylbenzimidazole-4-carboxylic acid Chemical compound C1=NC=2C(C(=O)O)=CC=CC=2N1N1CCOCC1 ZPKCFVXUDUWSBB-UHFFFAOYSA-N 0.000 description 1
- 206010000860 Acute megakaryocytic leukaemia Diseases 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010020243 Hodgkin's disease Diseases 0.000 description 1
- 201000006743 Hodgkin's lymphoma Diseases 0.000 description 1
- 208000006695 Leukemia, Megakaryoblastic, Acute Diseases 0.000 description 1
- 210000002966 Serum Anatomy 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000001605 fetal Effects 0.000 description 1
- 239000001963 growth media Substances 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 210000001519 tissues Anatomy 0.000 description 1
- 210000004881 tumor cells Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361879895P | 2013-09-19 | 2013-09-19 | |
| US61/879,895 | 2013-09-19 | ||
| PCT/US2014/055816 WO2015042029A1 (en) | 2013-09-19 | 2014-09-16 | Combination drug therapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018101120A Division JP6563558B2 (ja) | 2013-09-19 | 2018-05-28 | 組み合わせ薬物療法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016530208A JP2016530208A (ja) | 2016-09-29 |
| JP2016530208A5 true JP2016530208A5 (US07794700-20100914-C00152.png) | 2017-08-24 |
| JP6346944B2 JP6346944B2 (ja) | 2018-06-20 |
Family
ID=52689320
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016515414A Expired - Fee Related JP6346944B2 (ja) | 2013-09-19 | 2014-09-16 | 組み合わせ薬物療法 |
| JP2018101120A Expired - Fee Related JP6563558B2 (ja) | 2013-09-19 | 2018-05-28 | 組み合わせ薬物療法 |
| JP2019135772A Pending JP2019196391A (ja) | 2013-09-19 | 2019-07-24 | 組み合わせ薬物療法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018101120A Expired - Fee Related JP6563558B2 (ja) | 2013-09-19 | 2018-05-28 | 組み合わせ薬物療法 |
| JP2019135772A Pending JP2019196391A (ja) | 2013-09-19 | 2019-07-24 | 組み合わせ薬物療法 |
Country Status (10)
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2014321456B2 (en) * | 2013-09-19 | 2018-05-24 | Glaxosmithkline Llc | Combination drug therapy |
| US10206949B2 (en) | 2015-09-21 | 2019-02-19 | Ofer Agam | Composition that relieves heartburn, GERD and hangovers |
| WO2017156350A1 (en) | 2016-03-09 | 2017-09-14 | K-Gen, Inc. | Methods of cancer treatment |
| WO2020097318A1 (en) * | 2018-11-09 | 2020-05-14 | Dana-Farber Cancer Institute, Inc. | Targeting the oncogenic transcription factor stat5 with mineralocorticoid analogues |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2444085T3 (en) * | 2005-05-13 | 2015-04-27 | Univ California | Diarylhydantoinforbindelser as androgenreceptorantagonister for treating cancer |
| US7709517B2 (en) * | 2005-05-13 | 2010-05-04 | The Regents Of The University Of California | Diarylhydantoin compounds |
| EA017265B1 (ru) * | 2006-02-03 | 2012-11-30 | Имклоун Элэлси | Применение антитела imc-a12, которое является ингибитором igf-ir, для лечения рака предстательной железы |
| DK2656841T3 (en) * | 2006-03-27 | 2016-12-05 | Univ California | Androgen receptor MODULATOR FOR THE TREATMENT OF PROSTATE CANCER AND androgen receptor-ASSOCIATED DISEASES |
| EP2538785B1 (en) * | 2010-02-24 | 2018-03-21 | Medivation Prostate Therapeutics LLC | Processes for the synthesis of diarylthiohydantoin and diarylhydantoin compounds |
| US20130196990A1 (en) * | 2010-10-06 | 2013-08-01 | Junya Qu | Benzimidazole Derivatives As PI3 Kinase Inhibitors |
| CA2829322C (en) * | 2011-03-10 | 2017-01-10 | Suzhou Kintor Pharmaceuticals, Inc. | Substituted thioimidazolidinone androgen receptor antagonists and uses thereof |
| CN103159680A (zh) * | 2011-12-14 | 2013-06-19 | 爱美尼迪药物有限公司 | 咪唑二酮类化合物及其用途 |
| KR20150103735A (ko) * | 2013-01-09 | 2015-09-11 | 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 | 조합물 |
| JOP20200097A1 (ar) * | 2013-01-15 | 2017-06-16 | Aragon Pharmaceuticals Inc | معدل مستقبل أندروجين واستخداماته |
| AU2014321456B2 (en) * | 2013-09-19 | 2018-05-24 | Glaxosmithkline Llc | Combination drug therapy |
-
2014
- 2014-09-16 AU AU2014321456A patent/AU2014321456B2/en not_active Ceased
- 2014-09-16 WO PCT/US2014/055816 patent/WO2015042029A1/en active Application Filing
- 2014-09-16 BR BR112016005000A patent/BR112016005000A8/pt not_active IP Right Cessation
- 2014-09-16 EP EP14846138.7A patent/EP3046556A4/en not_active Withdrawn
- 2014-09-16 KR KR1020167009965A patent/KR20160055911A/ko not_active Application Discontinuation
- 2014-09-16 US US15/022,561 patent/US20160228446A1/en not_active Abandoned
- 2014-09-16 CA CA2921156A patent/CA2921156A1/en not_active Abandoned
- 2014-09-16 RU RU2016110546A patent/RU2016110546A/ru not_active Application Discontinuation
- 2014-09-16 CN CN201480051583.9A patent/CN105530934A/zh active Pending
- 2014-09-16 JP JP2016515414A patent/JP6346944B2/ja not_active Expired - Fee Related
-
2018
- 2018-05-28 JP JP2018101120A patent/JP6563558B2/ja not_active Expired - Fee Related
-
2019
- 2019-07-24 JP JP2019135772A patent/JP2019196391A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2665539T3 (es) | Derivados de benzamida para inhibir la actividad de ABL1, ABL2 y BCR-ABL1 | |
| JP2021059579A (ja) | 癌を処置するための医薬組合せ | |
| KR20140130179A (ko) | 벰루페닙 및 mdm2 억제제의, 증식성 질환 치료용 복합 요법 | |
| JP2007529421A5 (US07794700-20100914-C00152.png) | ||
| RU2014131390A (ru) | ПРОИЗВОДНЫЕ ТИЕНО[3,2-d]ПИРИМИДИНА, ОБЛАДАЮЩИЕ ИНГИБИРУЮЩЕЙ АКТИВНОСТЬЮ В ОТНОШЕНИИ ПРОТЕИНКИНАЗ | |
| NZ594322A (en) | Poly (ADP-Ribose) Polymerase (PARP) Inhibitors | |
| JP2006514689A5 (ja) | １−オキソ−２−（２，６−ジオキソピペリジン−３−イル）−４−メチルイソインドリンを含む脳腫瘍の治療及び管理のための医薬組成物 | |
| ES2644870T3 (es) | Derivados de oxatiazina como agentes antibacterianos y anticancerígenos | |
| TW200614992A (en) | Combinations for the treatment of diseases involving cell proliferation | |
| MX2012002179A (es) | Compuestos heterociclicos de oxima. | |
| AU2012255935B2 (en) | Compounds for use in treatment of mucositis | |
| MY144655A (en) | Pyrimidine urea derivatives as kinase inhibitors | |
| JP2009506054A5 (US07794700-20100914-C00152.png) | ||
| JP2009524668A5 (US07794700-20100914-C00152.png) | ||
| ES2866883T3 (es) | Combinaciones farmacéuticas para el tratamiento del cáncer | |
| JP2016517888A5 (US07794700-20100914-C00152.png) | ||
| ITBO20110012A1 (it) | Composizioni farmaceutiche comprendenti rifaximina e loro uso. | |
| JP2016530208A5 (US07794700-20100914-C00152.png) | ||
| NZ587202A (en) | Methods for measuring a patient response upon administration of a drug and compositions thereof | |
| CN103402519A (zh) | 肿瘤治疗剂 | |
| MX2011010732A (es) | Pirimidinas sustituidas por imidazol utiles en el tratamiento de trastornos relacionados con glucogeno sintasa cinasa 3 como la enfermedad de alzheimer. | |
| RU2016116789A (ru) | Комбинация энзалутамида и афурезертиба для лечения рака | |
| JOP20220063A1 (ar) | مشتقات بيريدازين-3(2h)-أون ملتحمة بأزول | |
| JP2011500805A5 (US07794700-20100914-C00152.png) | ||
| RU2016110546A (ru) | Комбинированная лекарственная терапия |
